The Filings Report

Baxter International Inc.

BAXNYSECIK 10456Healthcare / Medical Devicesfiscal year ends December74 quarters since 2008

Revenue, Q3 FY2026
$3.0B
+5.0% on Q3 FY2025
Net income
$294M
+739.1% on Q3 FY2025
Free cash flow
—
no year-earlier figure
Diluted EPS
$0.57
+733.3% on Q3 FY2025
Revenue, TTM
$11.6B
trailing four quarters
Net margin, TTM
-6.2%
net income −$723M
Free cash flow, TTM
—
Cash and equivalents
$2.0B
long-term debt —, Sep 30, 2026
Shares, 12-month change
+0.6%
517M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
$102M
0.8% of market value
Market value
$12.5B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Baxter International Inc. reported revenue of $3.0B, +5.0% on Q3 FY2025, and net income of $294M (+739.1%). Net income this quarter is driven by non-operating items: $253M of other income against $225M of operating income, so it reflects gains or losses outside the operations. Operating margin was 7.6%. Diluted earnings per share were $0.57.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.

Revenue and net incomeRevenueNet income
−$2B$0$2B$4BQ4'22, Net income: $181MQ4'22Q1'23, Revenue: $2.4BQ1'23, Net income: $44MQ1'23Q2'23, Revenue: $2.6BQ2'23, Net income: −$141MQ2'23Q3'23, Revenue: $2.6BQ3'23, Net income: $2.5BQ3'23Q4'23, Revenue: $2.7BQ4'23, Net income: $245MQ4'23Q1'24, Revenue: $2.5BQ1'24, Net income: $37MQ1'24Q2'24, Revenue: $2.7BQ2'24, Net income: −$314MQ2'24Q3'24, Revenue: $2.7BQ3'24, Net income: $140MQ3'24Q4'24, Revenue: $2.8BQ4'24, Net income: −$512MQ4'24Q1'25, Revenue: $2.6BQ1'25, Net income: $126MQ1'25Q2'25, Revenue: $2.8BQ2'25, Net income: $91MQ2'25Q3'25, Revenue: $2.8BQ3'25, Net income: −$46MQ3'25Q4'25, Revenue: $3.0BQ4'25, Net income: −$1.1BQ4'25Q1'26, Revenue: $2.7BQ1'26, Net income: −$15MQ1'26Q2'26, Revenue: $3.0BQ2'26, Net income: $126MQ2'26Q3'26, Revenue: $3.0BQ3'26, Net income: $294MQ3'26−$2B$0$2B$4BQ4'22, Net income: $181MQ1'23, Revenue: $2.4BQ1'23, Net income: $44MQ1'23Q2'23, Revenue: $2.6BQ2'23, Net income: −$141MQ3'23, Revenue: $2.6BQ3'23, Net income: $2.5BQ3'23Q4'23, Revenue: $2.7BQ4'23, Net income: $245MQ1'24, Revenue: $2.5BQ1'24, Net income: $37MQ1'24Q2'24, Revenue: $2.7BQ2'24, Net income: −$314MQ3'24, Revenue: $2.7BQ3'24, Net income: $140MQ3'24Q4'24, Revenue: $2.8BQ4'24, Net income: −$512MQ1'25, Revenue: $2.6BQ1'25, Net income: $126MQ1'25Q2'25, Revenue: $2.8BQ2'25, Net income: $91MQ3'25, Revenue: $2.8BQ3'25, Net income: −$46MQ3'25Q4'25, Revenue: $3.0BQ4'25, Net income: −$1.1BQ1'26, Revenue: $2.7BQ1'26, Net income: −$15MQ1'26Q2'26, Revenue: $3.0BQ2'26, Net income: $126MQ3'26, Revenue: $3.0BQ3'26, Net income: $294MQ3'26

Net income losses drawn in red.

Free cash flow
$0$200M$400M$600M$800MQ4'22, Free cash flow: $500MQ4'22Q1'23, Free cash flow: $307MQ1'23Q2'23, Free cash flow: $195MQ2'23Q3'23, Free cash flow: $191MQ3'23Q4'23, Free cash flow: $601MQ4'23Q1'24Q2'24Q3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26$0$200M$400M$600M$800MQ4'22, Free cash flow: $500MQ1'23, Free cash flow: $307MQ1'23Q2'23, Free cash flow: $195MQ3'23, Free cash flow: $191MQ3'23Q4'23, Free cash flow: $601MQ1'24Q3'24Q1'25Q3'25Q1'26Q3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$5B$10B$15B$20BQ4'22, Cash and equivalents: $1.6BQ4'22, Long-term debt: $16.7BQ4'22Q1'23, Cash and equivalents: $1.7BQ1'23Q2'23, Cash and equivalents: $1.7BQ2'23Q3'23, Cash and equivalents: $5.7BQ3'23Q4'23, Cash and equivalents: $3.1BQ4'23, Long-term debt: $13.9BQ4'23Q1'24, Cash and equivalents: $2.8BQ1'24Q2'24, Cash and equivalents: $1.6BQ2'24Q3'24, Cash and equivalents: $1.4BQ3'24Q4'24, Cash and equivalents: $1.8BQ4'24, Long-term debt: $13.2BQ4'24Q1'25, Cash and equivalents: $2.3BQ1'25Q2'25, Cash and equivalents: $1.7BQ2'25Q3'25, Cash and equivalents: $1.7BQ3'25Q4'25, Cash and equivalents: $2.0BQ4'25, Long-term debt: $9.4BQ4'25Q1'26, Cash and equivalents: $2.0BQ1'26Q2'26, Cash and equivalents: $2.1BQ2'26Q3'26, Cash and equivalents: $2.0BQ3'26$0$5B$10B$15B$20BQ4'22, Cash and equivalents: $1.6BQ4'22, Long-term debt: $16.7BQ1'23, Cash and equivalents: $1.7BQ1'23Q2'23, Cash and equivalents: $1.7BQ3'23, Cash and equivalents: $5.7BQ3'23Q4'23, Cash and equivalents: $3.1BQ4'23, Long-term debt: $13.9BQ1'24, Cash and equivalents: $2.8BQ1'24Q2'24, Cash and equivalents: $1.6BQ3'24, Cash and equivalents: $1.4BQ3'24Q4'24, Cash and equivalents: $1.8BQ4'24, Long-term debt: $13.2BQ1'25, Cash and equivalents: $2.3BQ1'25Q2'25, Cash and equivalents: $1.7BQ3'25, Cash and equivalents: $1.7BQ3'25Q4'25, Cash and equivalents: $2.0BQ4'25, Long-term debt: $9.4BQ1'26, Cash and equivalents: $2.0BQ1'26Q2'26, Cash and equivalents: $2.1BQ3'26, Cash and equivalents: $2.0BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Baxter International Inc. income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 21, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue2,9762,9602,7012,9742,8352,8102,6252,753+5.0%
Cost of revenue1,9821,9281,8102,3971,8851,8191,7641,794+5.1%
Gross profit9941,032891577950991861959+4.6%
Research and development125129139126118134140211+5.9%
Selling, general and administrative730735728761708718703761+3.1%
Operating income22521766(729)17219158(435)+30.8%
Other income (expense)2535(6)317034+3514.3%
Pretax income417158(6)(756)121133(3)(521)+244.6%
Income tax119231127917211(67)(33)−30.8%
Net income294126(15)(1,128)(46)91126(512)+739.1%
Diluted EPS ($)0.570.24(0.03)—(0.09)0.180.25(1.00)+733.3%
Diluted shares (millions)520518515—514514514——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Baxter International Inc. balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 21, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents1,9752,1502,0171,9661,7261,6862,2941,764+14.4%
Short-term investments—————————
Total current assets6,8266,9896,8476,8726,9336,7497,0358,853−1.5%
Total assets19,41419,79119,84620,05521,06721,04621,30425,782−7.8%
Total current liabilities3,8093,5913,6932,9703,7752,9393,4816,511+0.9%
Long-term debt———9,438———13,180—
Total liabilities12,93913,61213,83013,95313,85313,75314,25018,758−6.6%
Stockholders’ equity6,5026,2066,0436,1297,2417,3207,0816,964−10.2%
Shares outstanding (millions)517517516514514514513512—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

Baxter International Inc. cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 30, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 12, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 21, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow558285213584237217(193)488+135.4%
Capital expenditures—————————
Free cash flow (CFO − capex)—————————
Depreciation and amortization239239237240237257247245+0.8%
Share repurchases—————————
Dividends paid55587878787147−94.3%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 12, 2026.

Income statement

Baxter International Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 21, 2025FY2023ended Dec 31, 2023filed Feb 8, 2024FY2022ended Dec 31, 2022filed Feb 9, 2023FY2021ended Dec 31, 2021filed Feb 23, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Mar 17, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 23, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Feb 21, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 23, 2012FY2010ended Dec 31, 2010filed Feb 23, 2011FY2009ended Dec 31, 2009filed Feb 23, 2010FY2008ended Dec 31, 2008filed Jul 28, 2009FY2007ended Dec 31, 2007filed Jul 28, 2009
Revenue11,24410,63610,36010,05712,14611,67311,36211,09910,58410,1639,96810,7199,41313,93613,89312,84312,56212,34811,263
Cost of revenue7,8656,6526,2106,5087,4267,0866,6016,3406,1106,0475,8226,1385,2516,8026,8476,8856,0376,2185,744
Gross profit3,3793,9844,1503,5494,7204,5874,7614,7594,4744,1164,1464,5814,1627,1347,0465,9586,5256,1305,519
Research and development5185905184505315215956546156466036105821,081946915917868760
Selling, general and administrative2,8902,9672,9533,0972,8452,4692,5352,6202,6272,7253,0943,3153,0843,2833,1542,9072,7312,6982,521
Operating income(308)14707(2,845)1,3501,6161,7721,5841,288745449656496——————
Other income (expense)4138(26)(9)(41)(190)(731)78(133)4,275105(21)7155(83)(159)(45)(26)(18)
Pretax income(505)(289)242(3,248)1,1161,2929701,6171,1004,9544284903752,8382,8091,8902,7342,4622,128
Income tax3953761(135)83182(41)65491(12)353360555553463519437407
Net income(957)(649)2,656(2,433)1,2841,1021,0011,5466024,9659682,4972,0122,3262,2241,4202,2052,0141,707
Diluted EPS ($)(1.87)(1.27)5.23(4.83)2.532.131.932.831.089.011.764.563.664.183.882.393.593.162.61
Diluted shares (millions)513510508504508517519546555551549547549556573594614637654

Balance sheet

Baxter International Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 21, 2025FY2023ended Dec 31, 2023filed Feb 8, 2024FY2022ended Dec 31, 2022filed Feb 9, 2023FY2021ended Dec 31, 2021filed Feb 23, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Mar 17, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 23, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Feb 21, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 23, 2012FY2010ended Dec 31, 2010filed Feb 23, 2011FY2009ended Dec 31, 2009filed Feb 23, 2010FY2008ended Dec 31, 2008filed Jul 28, 2009FY2007ended Dec 31, 2007filed Jul 28, 2009
Cash and equivalents1,9661,7643,0781,6212,9513,7303,3351,8383,3942,8012,2132,9252,7333,2702,9052,6852,7862,1312,539
Short-term investments——————————5,148————————
Total current assets6,8728,8539,6008,0118,8728,4117,5035,9597,2636,57411,79610,16210,1959,2608,6507,9898,2717,148—
Total assets20,05525,78228,27628,28733,52120,01918,19315,72017,11115,54620,96226,13825,22420,39019,07317,48917,35415,405—
Total current liabilities2,9706,5116,5034,7454,2363,3333,2302,8142,8212,7445,7506,0375,2484,7594,8574,0414,4643,635—
Long-term debt9,43813,18013,85516,70217,7546,233—————————————
Total liabilities13,95318,75819,80822,39224,40011,29310,2817,8547,995——————————
Stockholders’ equity6,1296,9648,4025,8339,0778,6897,8827,8449,1248,2908,8468,1208,4636,9386,5856,5677,1916,229—
Shares outstanding (millions)514512508505502505507513540540548543543546560579603——

Cash flow statement

Baxter International Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 12, 2026FY2024ended Dec 31, 2024filed Feb 21, 2025FY2023ended Dec 31, 2023filed Feb 8, 2024FY2022ended Dec 31, 2022filed Feb 9, 2023FY2021ended Dec 31, 2021filed Feb 23, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Mar 17, 2020FY2018ended Dec 31, 2018filed Feb 21, 2019FY2017ended Dec 31, 2017filed Feb 23, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Feb 21, 2014FY2012ended Dec 31, 2012filed Feb 21, 2013FY2011ended Dec 31, 2011filed Feb 23, 2012FY2010ended Dec 31, 2010filed Feb 23, 2011FY2009ended Dec 31, 2009filed Feb 23, 2010FY2008ended Dec 31, 2008filed Jul 28, 2009FY2007ended Dec 31, 2007filed Jul 28, 2009
Operating cash flow8451,0191,7261,2112,2221,8682,1042,0171,7141,6541,7713,2153,1983,1062,8173,0032,9092,5152,305
Capital expenditures5134464323776917096966596167199119257061,1619609631,014954692
Free cash flow (CFO − capex)3325731,2948341,5311,1591,4081,3581,0989358602,2902,4921,9451,8572,0401,8951,5611,613
Depreciation and amortization9819979841,072867823789771750800759792635712670685638631581
Share repurchases—00326005001,2702,452564292—5509131,4801,5831,4531,2161,9861,855
Dividends paid3485905865735304734233763152689101,0951,023804709688632546704

Insider activity

Form 4 filings by officers, directors and 10% owners, November 3, 2024 to November 3, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$0
0 sales by 0 insiders; officers and directors $0
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$0
0 sales by 0 insiders; officers and directors $0

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 2, 2026Hider Andrew P.President and CEO, Directortax withholding54,276$25.70$1M518,447Sep 3, 2026
Sep 2, 2026Foster JuliePresident, Front Line Caretax withholding2,098$25.70$54K29,164Sep 3, 2026
Sep 1, 2026Teaff JamesPresident, CCStax withholding750$25.48$19K30,370Sep 3, 2026
Jun 2, 2026Wallace Steven P.President, Adv. Surgerytax withholding153$18.68$3K70,128Jun 3, 2026
Jun 2, 2026Teaff JamesPresident, CCStax withholding321$18.68$6K31,063Jun 3, 2026
Jun 1, 2026Zielinski Anita ASVP, Interim CFO, CAO & Cntrlraward13,426$0.00—59,714Jun 3, 2026
May 5, 2026Wilkes David S.Directoraward12,836$0.00—37,076May 7, 2026
May 5, 2026Wendell Amy McBrideDirectoraward12,836$0.00—44,235May 7, 2026
May 5, 2026Schlichting Nancy MDirectoraward12,836$0.00—34,994May 7, 2026
May 5, 2026Morrison PatriciaDirectoraward12,836$0.00—42,386May 7, 2026
May 5, 2026Shafer David BrentDirectoraward12,836$0.00—72,804May 7, 2026
May 5, 2026McDonnell Michael R.Directoraward12,836$0.00—14,647May 7, 2026
May 5, 2026Craig Jeffrey ADirectoraward12,836$0.00—23,662May 7, 2026
May 5, 2026Ampofo William A. IIDirectoraward12,836$0.00—30,375May 7, 2026
Mar 6, 2026Zielinski Anita ASVP, CAO and Controllertax withholding1,932$17.69$34K46,281Mar 10, 2026
Mar 6, 2026Soriano Maria CeciliaGroup Pres., ITT & Pharma.tax withholding2,848$17.69$50K75,045Mar 10, 2026
Mar 6, 2026Rosenbloom David S.EVP and General Counseltax withholding6,620$17.69$117K138,216Mar 10, 2026
Mar 6, 2026Rasul ReazurEVP,Group Pres,Healthcaretax withholding12,674$17.69$224K125,557Mar 10, 2026
Mar 6, 2026Grade Joel T.EVP and CFOtax withholding8,153$17.69$144K271,674Mar 10, 2026
Mar 2, 2026Rasul ReazurEVP,Group Pres,Healthcaretax withholding1,614$19.69$32K138,231Mar 3, 2026
Mar 2, 2026Soriano Maria CeciliaGroup Pres., ITT & Pharma.tax withholding1,852$19.69$36K77,894Mar 3, 2026
Mar 2, 2026Rosenbloom David S.EVP and General Counseltax withholding1,336$19.69$26K144,837Mar 3, 2026
Feb 27, 2026Hider Andrew P.President and CEO, Directoraward201,804$0.00—572,239Mar 3, 2026
Feb 27, 2026Carlisle CynthiaExecutive Vice President, CHROaward17,806$0.00—17,806Mar 3, 2026
Feb 27, 2026Carlisle CynthiaExecutive Vice President, CHROaward11,871$0.00—29,677Mar 3, 2026

Full insider history for Baxter International Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
BAXTER INTERNATIONAL INC., CIK 10456 on EDGAR
Extract generated
November 4, 2026
Withheld
20 line-years whose four quarters do not sum to the filed year: pretax income FY2010, gross profit FY2012, revenue FY2012, cost of revenue FY2013, gross profit FY2013, revenue FY2013, depreciation amortization FY2014, cost of revenue FY2014, opex sga FY2014, rnd FY2014, net income FY2017, gross profit FY2022, operating income FY2022, pretax income FY2022, revenue FY2022, cost of revenue FY2023, operating income FY2023, opex sga FY2023, pretax income FY2023, rnd FY2023
Repaired
6 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: income tax FY2013, pretax income FY2013, income tax FY2014, pretax income FY2014, income tax FY2024, operating income FY2024
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends, PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated November 4, 2026.

JSON file
/data/financials/BAX.json